We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+46.74%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.57B
AUM Growth
+$1.21B
Cap. Flow
+$318M
Cap. Flow %
8.9%
Top 10 Hldgs %
45.04%
Holding
142
New
39
Increased
22
Reduced
59
Closed
10

Top Buys

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$68.1M
2
GBIO
Generation Bio
GBIO
+$62.7M
3
RPRX icon
Royalty Pharma
RPRX
+$37.1M
4
ONC
BeOne Medicines Ltd
ONC
+$32.6M
5
NG icon
NovaGold Resources
NG
+$26.3M

Top Sells

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$137M
2
AVTR icon
Avantor
AVTR
+$40.7M
3
PYPL icon
PayPal
PYPL
+$33.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27M
5
Z icon
Zillow
Z
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 61.98%
2 Consumer Discretionary 13.38%
3 Technology 3.16%
4 Financials 1.15%
5 Communication Services 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
76
Regenxbio
RGNX
$616M
$8.62M 0.24%
234,000
-16,000
-6% -$596K
KRYS icon
77
Krystal Biotech
KRYS
$10.7B
$8.28M 0.23%
200,000
+100,000
+100% +$4.81M
RNAC icon
78
Cartesian Therapeutics
RNAC
$223M
$8.24M 0.23%
96,667
-17,121
-15% -$1.55M
IMMU
79
DELISTED
Immunomedics Inc
IMMU
$8.18M 0.23%
+230,838
New +$6.75M
TCDA
80
DELISTED
Tricida, Inc. Common Stock
TCDA
$7.83M 0.22%
285,000
-75,000
-21% -$2.04M
AKBA icon
81
Akebia Therapeutics
AKBA
$335M
$7.79M 0.22%
574,000
+149,000
+35% +$1.54M
MLCO icon
82
CALL
Melco Resorts & Entertainment
MLCO
$2.2B
$7.76M 0.22%
500,000
– –
TRIL
83
DELISTED
Trillium Therapeutics Inc.
TRIL
$7.71M 0.22%
953,000
-47,000
-5% -$291K
PRQR icon
84
ProQR Therapeutics
PRQR
$246M
$7.66M 0.21%
1,259,177
-40,823
-3% -$221K
BRKR icon
85
Bruker
BRKR
$9.43B
$7.5M 0.21%
+184,500
New +$7.26M
SPRO icon
86
Spero Therapeutics
SPRO
$68.9M
$7.37M 0.21%
545,040
-30,960
-5% -$348K
IMUX icon
87
Immunic
IMUX
$177M
$7.27M 0.2%
60,000
-3,002
-5% -$305K
HOOK
88
DELISTED
HOOKIPA Pharma
HOOK
$6.97M 0.2%
59,962
-19,664
-25% -$1.92M
STOK icon
89
Stoke Therapeutics
STOK
$1.81B
$6.79M 0.19%
285,000
+35,000
+14% +$831K
ACIU icon
90
AC Immune
ACIU
$231M
$6.63M 0.19%
984,550
-15,450
-2% -$112K
APTX
91
DELISTED
Aptinyx Inc. Common Stock
APTX
$6.59M 0.18%
1,581,090
-85,576
-5% -$290K
AAL icon
92
CALL
American Airlines Group
AAL
$9.96B
$6.54M 0.18%
500,000
– –
AUTL
93
Autolus Therapeutics
AUTL
$381M
$6.41M 0.18%
400,000
-100,000
-20% -$1.11M
PASG icon
94
Passage Bio
PASG
$14.9M
$6.39M 0.18%
11,700
-800
-6% -$360K
ADCT icon
95
ADC Therapeutics
ADCT
$139M
$6.37M 0.18%
+136,000
New +$5.16M
CYPH
96
Cypherpunk Technologies Inc
CYPH
$64.3M
$6.22M 0.17%
297,400
+272,400
+1,090% +$5.84M
MRUS
97
DELISTED
Merus
MRUS
$6.18M 0.17%
384,000
-116,000
-23% -$1.68M
HTHT icon
98
Huazhu Hotels Group
HTHT
$13.4B
$6.13M 0.17%
+175,000
New +$5.82M
TSM icon
99
CALL
TSMC
TSM
$1.96T
$5.68M 0.16%
+100,000
New +$5.27M
NKTR icon
100
Nektar Therapeutics
NKTR
$2.31B
$5.54M 0.15%
+15,933
New +$4.97M
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2020 Portfolio in Review

As of Q2 2020, Artal Group held 142 positions worth $3.57B, up 51% from $2.37B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Artal Group deployed $318M of net new capital in Q2 2020, opening 39 new positions and adding to 22 existing holdings. Its largest new stake was GDS Holdings: 1,100,000 shares worth $87.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 69% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Moderna, an estimated $137M trimmed.

  • Artal Group's largest Q2 2020 buy was GDS Holdings: 1,100,000 shares worth $87.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q2 2020, an estimated $32.6M increase.
  • Artal Group's biggest Q2 2020 reduction was Moderna, cutting an estimated $137M.
  • Artal Group fully exited Arrowhead Research in Q2 2020, selling an estimated $17.3M.
  • Artal Group's ten largest holdings make up 45% of its $3.57B portfolio in Q2 2020.
  • Artal Group opened 39 new positions and closed 10 in Q2 2020.
  • Artal Group's portfolio value rose 51% quarter-over-quarter to $3.57B.

Based on Artal Group's 13F filing for Q2 2020, filed 14 Aug 2020.